San Francisco, California, November 14, 2018: A recent market research report by TMR Research presents a detailed analytical assessment of the growth prospects of the global market for combi-chem and high throughput screening from 2017 to 2025. The report is titled “Combi-chem & High Throughput Screening Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025.”
The report states that the market has gained pace in the past few years owing to the increased utilization of these techniques in the field of drug discovery. As the financial and socio-economic burden of chronic diseases such as cardiovascular diseases, diabetes, and cancer rises at an alarming pace across the globe, funds and resources diverted towards drug discovery are rising massively. Thus this factor is likely to remain one of the leading growth drivers for the market in the next few years as well.
Get Sample Copy of this Report @
From a geographical standpoint, the combi-chem and high throughput screening markets in Europe and North America collectively account for the biggest piece in the revenue pie of the global market. Factors such as the vast rise in prevalence of chronic and infectious diseases and the rising awareness regarding the benefits of early and timely diagnosis of cancer have worked well for these regional markets.
In the next few years, the market in Asia Pacific is likely to emerge as the most promising regional market for combi-chem and high throughput screening as the number of drug manufacturing facilities increase, funds invested on R&D activities associated with drug discovery rise, and the burden of chronic diseases increases. The region will also benefit from rising disposable incomes and increased expenditure on healthcare and wellness.
Read Comprehensive Overview of Report @
Some of the leading companies operating in the global combi-chem and high throughput screening market are Sanofi-Aventis, Abbott Healthcare, Merck & Co., AstraZeneca PLC, and Pfizer, Inc.